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1. Introduction 
Gluten-free diet is an effective therapy for celiac disease. There are few diseases in medicine 
where a nutritional intervention alone can produce such rapid, gratifying results. One may 
therefore question the need for following these patients long-term. In the past, a rather 
simplistic approach was taken towards treatment and follow-up of patients with celiac 
disease. “Go home, don’t eat anything with gluten and you’ll be fine”, patients were told. 
But as more individuals were diagnosed with celiac disease and our understanding of this 
disorder improved, several important issues emerged. Firstly, it was recognized that gluten-
free diet is complex, costly and socially restrictive, and that cross contamination of the diet 
with gluten was very common. For a gluten-free diet to be fully effective, adherence to the 
diet must be strict and life-long, thereby adding further challenges. Gluten-free diet should 
be viewed as a “prescribed therapy” rather than a mere change in life style. Furthermore, 
celiac disease is not simply a malabsorptive gastrointestinal disorder. It is a multisystem, 
auto-immune disease that carries a significant health burden and risk of complications 
(Freeman et al. 2011). These factors necessitate ongoing, careful monitoring of patients with 
celiac disease. The following six key elements of management of celiac disease include long-
term follow-up (NIH, 2004): 
Consultation with a skilled dietitian 
Education about the disease 
Lifelong adherence to a gluten-free diet 
Identification and treatment of nutritional deficiencies 
Access to an advocacy group 
Continuous long-term follow-up by a multidisciplinary team 
This chapter highlights the important issues in long-term follow-up of patients with celiac 
disease and offers guidelines for practicing physicians and allied health professionals 
involved in their management. Issues around the diagnosis of celiac disease and details of 
the gluten-free diet will not be covered. Because this is a rapidly evolving field, 
recommendations for follow-up may get modified over time. 
2. Importance of follow-up 
Because most patients with celiac disease recover symptomatically with therapy they may 
not perceive the need for follow-up. This view may be shared by some of their health care 
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providers. Hence, not all patients with celiac disease receive regular follow-up care. In a 
study of 126 adults with celiac disease in United Kingdom, only 62% were receiving formal 
follow-up care (Bebb et al., 2006). Of these, 92% were being followed at a hospital clinic and 
8% by their general practitioner. 
Follow-up is essential not only to assess symptomatic recovery and to monitor 
complications but also to assist the patient in adhering to the diet (Pietzak, 2005). Follow-up 
care is the key to dietary compliance. There is good objective evidence that proactive follow-
up measures can reinforce adherence to the gluten-free diet, both in children and adults 
(Bardella et al. 1994, Hogberg et al. 2003, Ljugman & Myrdal, 1993, Lamontagne et al, 2001). 
Follow-up visits also provide an opportunity to give patients updated information on new 
developments in the field. 
3. Who should provide follow-up? 
Gastroenterologists are often the ones who establish or confirm the diagnosis of celiac 
disease. But who should provide their long term follow-up care… the patient’s family 
physician, internist/paediatrician or the gastroenterologist? A survey of Canadian 
gastroenterologists revealed that 76% routinely provided long-term follow-up care to 
patients with celiac disease (Silvester & Rashid, 2010). Significantly more paediatric 
gastroenterologists provided long-term follow-up, as compared with adult 
gastroenterologists. Also, the elements of follow-up varied, including the frequency of 
laboratory testing and of repeat duodenal biopsies. The most commonly cited reason (86%) 
for not providing long-term follow-up was that the patient`s primary care physician was 
providing this care. Other reasons included, a) not having an organized system to recall 
patients; b) lack of time and c) the belief that follow-up was not required once the patient 
was on a gluten-free diet. In some cases, the patients themselves did not want follow-up.  
Who eventually provides long-term care to patients with celiac disease may depend on the 
availability of resources, both personnel and funding, the severity of the patient’s illness and 
the complexity of the disease course. It is probably prudent that all patients be followed by 
their gastroenterologists for at least the first year after diagnosis. Thereafter, the family 
physician or internist can follow the patient and request gastroenterologist’s input as 
needed. All children with celiac disease should be followed by either their pediatricians or 
gastroenterologist.  
There is less controversy about the role of the dietitian in follow-up of these patients. 
Treatment of celiac disease is primarily nutritional and the dietitian’s role is therefore of 
paramount importance. In one survey, the preferred method of follow-up by most patients 
was to see a dietitian with a doctor being available (Bebb et al. 2006).  
Nutritional adequacy of a gluten-free diet is also a concern because it may be deficient in 
certain vitamins, iron, calcium and fiber (Kupper, 2005). These micronutrient deficiencies 
require monitoring which is best provided by a dietitian. However, a gluten-free diet is 
complex and not all dietitians are well-versed in this area. Therefore, ongoing nutritional 
counseling should be provided by a dietitian skilled in the use of a gluten-free diet (Case, 
2005). 
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4. What constitutes appropriate follow-up? 
Evaluation of current practice guidelines issued by various professional organizations has 
revealed significant differences in recommendations for long-term follow-up of patients 
with celiac disease (Silvester & Rashid, 2007). As information accumulates, broad guidelines 
for long-term management are beginning to emerge (Haines et al, 2008, AGA, 2006, Hill et 
al, 2005). While there is consensus on some aspects, others remain controversial. 
Celiac disease has a wide clinical spectrum. In order to individualize the type of follow-up 
needed, it is important to stratify patients according to their risk of developing 
complications. Genetic factors strongly influence the development of celiac disease; 
specifically, the major histocompatibility complex class II antigens. About 90% of patients 
with celiac disease carry the HLA-DQ2 heterodimer encoded by alleles DQA1*05 and 
DQB1*02. The remainder have either HLA DQA1*05 or HLA DQB1*02, or express HLA-
DQ8 encoded by alleles DQA1*03 and DQB1*0302. The HLA-DQ2 and DQ8 are within 
haplotypes also associated with other autoimmune disorders such as type-1diabetes and 
autoimmune thyroid disease. Patients with celiac disease who are homozygous for HLA-
DQ2 tend to have more severe complications, including refractory celiac disease and 
enteropathy-associated T cell lymphoma (Al-Toma et al. 2006). The phenotype of patients 
who are homozygous for DQB1*02 tends to be associated with more severe symptoms, 
marked villous atrophy at diagnosis and slower recovery after instituting a gluten-free diet 
(Karinen et al. 2006, Jores et al. 2007). As our understanding of the genetics of celiac disease 
improves and HLA testing becomes more routinely available, it may be possible to identify 
patients who require more intensive follow-up. 
Follow-up of patients with celiac disease should focus on three key areas; nutritional 
deficiencies, adherence to gluten-free diet and monitoring of complications. A proposed 
follow-up plan is listed in Table 1.  
The physician’s assessment at each visit should include a complete history, especially noting 
symptoms of abdominal pain, diarrhoea, weight loss, anorexia and fatigue. Physical 
examination should include measurement of weight, height and body mass index (BMI). 
Children should be serially evaluated with a growth chart to detect alterations in growth 
velocity. A complete, systemic examination should be performed in all patients.  
The utility of serological testing and the usefulness of a repeat intestinal biopsy will be 
discussed later. 
Yearly monitoring of thyroid function is recommended as thyroid disease develops 
commonly in celiac disease (Elstrom et al. 2008, Meloni et al. 2009). Hypothyroidism can be 
easily identified by laboratory tests (thyroid stimulating hormone, free thyroxine) and 
treated with hormone replacement therapy. Thyroid antibody testing may not be cost 
effective as it does not necessarily predict the development of clinical thyroid dysfunction. 
Also, currently there are no means of preventing the development of thyroiditis or other 
auto-immune disorders such as type-1 diabetes. There is controversy whether a gluten-free 
diet prevents autoimmune thyroiditis that is established or is in evolution (Meloni et al. 
2009, Cassio et al, 2010).  
The follow-up plan listed in Table 1 is the minimum recommended for an average, 
uncomplicated patient with celiac disease. If the patient remains ill, additional investigations 
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At Diagnosis (Physician and Dietitian) 
  - Education on celiac disease 
  - Gluten-free dietary counseling by a skilled dietitian 
  - Recommend family screening 
  - Recommend membership in a celiac support group 
  - Bone densitometry* 
  - Celiac serology (if not previously obtained) 
  - Other Routine Tests (complete blood count, iron studies, folate, thyroid function tests, 
liver enzymes, calcium, phosphate, vitamin D) 
  
At 2 months (Physician and Dietitian) 
  - Assess symptoms and coping skills 
  - Dietary review 
 
At 6 months (Physician and Dietitian) 
  - Assess symptoms  
  - Complete physical examination 
  - Dietary review 
  - Celiac serology 
  - Repeat Other Routine Tests (if previously abnormal) 
 
At 12 months (Physician and Dietitian) 
  - Assess symptoms  
  - Complete physical examination 
  - Dietary review 
  - Celiac serology (if still positive) 
  - Repeat Other Routine Tests (if previously abnormal) 
  - Bone densitometry (if previously abnormal) 
  - Small intestinal biopsy* 
 
Yearly (Physician and Dietitian) 
  - Assess symptoms  
  - Complete physical examination 
  - Dietary review 
  - Celiac serology 
  - Thyroid function tests 
  - Other Tests (as clinically indicated) 
* Not recommended routinely for children. See text  
Table 1. Proposed Routine Follow-up Plan for Patients with Celiac Disease 
may be needed, as guided by the clinical findings. For example, micronutrients such as zinc 
should be measured in severe malnutrition. In patients with macrocytic anemia and normal 
folate, vitamin B12 status should be assessed by  measuring serum cobalamin, homocystine 
and methylmalonic acid. Any abnormalities detected should be followed up with 
appropriate retesting after supplementation. 
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Celiac disease can be associated with other autoimmune disorders, such as type I diabetes 
mellitus or thyroiditis. If a patient suffers from one or more of these, follow-up should 
include relevant assessment and investigations.  
Patients who remain symptomatic despite following a gluten-free diet may need to be seen 
more frequently, whereas those who were asymptomatic at diagnosis and remain so, may 
require less frequent visits. 
5. Follow-up of paediatric patients 
The general principles of management described above also apply to the paediatric 
population with a few notable differences. Growth sets children apart from adults. Celiac 
disease can adversely affect physical and neurodevelopmental growth, primarily due to 
nutritional deficiencies. Also, since very young children are unable to communicate their 
symptoms, a high index of suspicion should be maintained when inquiring about their 
health from the parents.  
In children, all anthropometric measurements should be plotted as percentiles on  growth 
charts. The BMI in children is not a fixed value but is age dependent and is expressed in 
percentiles. For children under three years of age, head circumference should also be 
measured. Poor growth implies a nutritional deficit. Normal growth is reassuring but does 
not rule out micronutrient deficiencies. 
According to the revised guidelines of the European Society for Paediatric Gastroenterology 
and Nutrition, in children older than 2 years of age with symptoms suggestive of celiac 
disease, the characteristic histologic findings on small intestinal biopsy and unequivocal 
clinical resolution after institution of a gluten-free diet, the diagnosis can be considered 
definitive for lifelong celiac disease without need for further biopsies (Walker-Smith et al. 
1990). A follow-up biopsy may be required only in selected patients in whom the diagnosis 
is in doubt, or if the child remains symptomatic despite being on a strict gluten-free diet.  
In children with celiac disease, secondary nutritional problems such as iron deficiency, 
anemia and osteoporosis resolve completely after starting a gluten-free diet. Once corrected, 
routine follow-up laboratory testing for these conditions is not required. 
6. Utility of serological testing in follow-up 
Serological tests usually become negative within a year on a strict gluten-free diet and may 
be used to monitor compliance with the gluten-free diet. However, these tests are 
insufficiently sensitive to reflect occasional dietary transgressions (Kaukinen et al. 2002, 
2007, Tursi et al. 2006). The degree and duration of gluten exposure will affect the results. 
Thus, these tests may be more useful in predicting non-adherence rather than strict 
adherence. Furthermore, normalization of the antibodies does not necessarily imply 
complete villous healing (Tursi et al. 2003). Some patients with normalized antibodies may 
have ongoing villous atrophy.  
A persistently positive serological test after a patient has been on a gluten-free diet is highly 
indicative of ongoing gluten exposure and may indicate mucosal injury or development of 
refractory celiac disease. A negative test is reassuring only to a certain degree.  
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7. Role of routine repeat small intestinal biopsy 
Small intestinal biopsy is the definitive way to document mucosal healing after starting a 
gluten-free diet. However, there is controversy as to whether all patients with celiac disease 
should undergo a follow-up biopsy to document intestinal healing. Some adult 
gastroenterologists routinely perform a follow-up biopsy in all patients after 12 months of 
starting a gluten-free diet. Others perform a biopsy only in selected cases. 
Rates of mucosal healing are highly variable. In some studies, up to 40% of patients had 
persisting villous atrophy after two years (Tursi et al, 2006) and about 10% after five years 
on a gluten-free diet (Wahab et al. 2002). This raises the question of whether symptoms 
alone constitute a reliable guide to mucosal healing (Kaukinen et al. 2007). Ongoing villous 
atrophy can lead to nutritional problems such as osteoporosis and may increase the risk of 
developing complications such as lymphoma. Clinical symptoms, celiac serology and 
laboratory markers of inflammation are not robust enough measures to confirm mucosal 
healing. Until better non-invasive tests of mucosal healing can be developed, a repeat 
intestinal biopsy after a year of gluten-free diet is recommended.  
Mucosal healing tends to be more rapid and more complete in children. Also, since 
endoscopy requires a general anesthetic in most cases, a repeat follow-up biopsy is not 
recommended in children with celiac disease who recover clinically and normalize their 
celiac antibody tests. 
8. Non-responsive celiac disease 
Most patients with celiac disease will improve and their symptoms will resolve after starting 
a gluten-free diet. However, some do not … a phenomenon referred to as non-responsive 
celiac disease. Non-responsive celiac disease is defined as failure to respond to at least six 
months of treatment with a gluten-free diet (primary) or re-emergence of symptoms or 
laboratory abnormalities typical of celiac disease while continuing on treatment with a 
gluten-free diet (secondary). The six months of treatment duration with gluten-free diet is 
used an arbitrary cut off point since patients should have significant improvement by this 
time.  
Non-responsive celiac disease is common. Among 603 patients followed at one health 
care facility over five years, 113 (19%) had non-responsive celiac disease (Leffler et al. 
2007).  
The causes of non-responsive celiac disease are listed in Table 2. Before embarking on any 
investigations, one must ensure that the diagnosis of celiac disease was correct in the first 
place. Of 55 patients referred to a tertiary care medical institution with a presumed 
diagnosis of non-responsive celiac disease, 6 (9.2%) did not have celiac disease (Abdulkarim 
et al. 2002). Some patients may self-diagnose and never undergo an intestinal biopsy. In 
others who do undergo intestinal biopsy, the specimen may get interpreted incorrectly. 
Furthermore, villous atrophy is not unique to celiac disease. Similar lesions can be seen in 
infectious, allergic or autoimmune enteropathy and in other disorders such as Crohn’s 
disease and collagenous sprue.  
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- Gluten exposure 
- Irritable bowel syndrome 
- Refractory celiac disease 
- Lactose intolerance 
- Pancreatic insufficiency 
- Microscopic colitis 
- Small intestinal bacterial overgrowth 
- Ulcerative jejunitis 
- Other co-existing conditions (gastroesophageal reflux disease, peptic ulcer, food 
allergy, eating disorder, inflammatory bowel disease, immunodeficiency) 
Table 2. Causes of Non-Responsive Celiac Disease 
Ongoing exposure to gluten in the diet is the most common cause of non-responsive celiac 
disease, occurring in 36% to 51% of patients (Leffler et al. 2007, Abdulkarim et al. 2002). The 
gluten exposure may be accidental or intentional. The recently proposed international 
definition of the gluten-free diet states that the  gluten content should be less than 20 parts 
per million (ppm) i.e. less than 20 mg gluten in 1 kg of dry weight food product (Codex 
Alimentarius Commission, Standard 118-1979, July 2008). Although individuals may have 
varying degrees of gluten tolerance, ingestion of 50 mg of gluten daily over three months 
can be sufficient to cause injury to the small intestinal mucosa (Catassi et al. 2007). For 
example, an average slice of bread contains approximately 3.0-3.5 gm of gluten. Hence, an 
amount as little as 1/70th of a slice of bread consumed on a regular basis may lead to villous 
damage. Avoiding gluten contamination in diet is very difficult for many patients because 
there are many hidden sources of gluten in the diet. In some cases, the patient may be 
knowingly consuming gluten-containing foods and, for whatever reason, does not tell the 
physician. (Some patients feel guilty or embarrassed in admitting dietary transgressions!). 
Furthermore, patients may believe that occasional consumption of small quantities of 
gluten-containing foods is safe. A dietitian with expertise in gluten-free diet can help 
evaluate gluten ingestion in such cases. 
After gluten ingestion, irritable bowel syndrome (IBS) is the second most common cause of 
non-responsive celiac disease. This is sometimes referred to as post-inflammatory IBS. A 
variety of symptoms including abdominal pain, diarrhoea and constipation can occur. The 
diagnosis is clinical and requires exclusion of other causes. The management is symptomatic 
and may include cognitive behavior therapy. 
The villous atrophy present at the time of diagnosis of celiac disease may lead to secondary 
lactose intolerance, causing symptoms such as abdominal pain, gas, bloating and diarrhoea. 
A breath hydrogen test may provide objective evidence of lactase deficiency. A trial of a 
lactose-free diet or lactase enzyme supplements may help alleviate the symptoms. Patients 
require calcium and vitamin D supplements while on a lactose-free diet. 
Microscopic colitis is an autoimmune inflammatory condition. There are two types, namely 
lymphocytic colitis and collagenous colitis. The main symptom is watery diarrhoea. A 
colonoscopy and biopsies are needed to make this diagnosis. Treatment includes a strict 
gluten-free diet and, in some cases drugs including 5-aminoslicylates, budesonide and 
azathioprine. 
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Pancreatic insufficiency may occur in some patients with celiac disease. The exact cause is 
unknown. Villous atrophy causing impaired secretion and action of enteric hormones such 
as enterokinase, cholecystokinin and secretin may play a role. Steatorrhoea and weight loss 
can occur. Tests for exocrine pancreatic insufficiency will be abnormal. Pancreatic enzyme 
replacement therapy and fat-soluble vitamin supplements should be prescribed. The 
problem is usually transient and pancreatic function recovers. 
A damaged small intestinal mucosa provides a nidus for bacterial growth. Bacterial 
overgrowth in the small bowel can lead to diarrhoea and weight loss from steatorrhoea. Iron 
and vitamin B12 deficiency can occur. While the diagnosis is confirmed by a small bowel 
aspirate for bacterial colony counts, a course of empiric antibiotic therapy may be 
recommended. Bacterial overgrowth can be successfully treated with oral antibiotics. 
Patients with celiac disease are at risk for developing other autoimmune disorders, most 
commonly autoimmune thyroid disease. Hypothyroidism can lead to a variety of 
symptoms that may mimic those of celiac disease, such as chronic fatigue and 
constipation. If celiac serology and intestinal biopsy are normal in a symptomatic patient 
who has good adherence to gluten-free diet, development of another autoimmune 
disorder should be considered. 
An approach to the assessment of patients with non-responsive celiac disease is described in 
Table 3.  If lymphoma is suspected, upper and lower gastrointestinal endoscopy, abdominal 
CT scan, capsule endoscopy, and possibly double-balloon enteroscopy should be 
considered. 
 
- Review of original diagnosis of celiac diagnosis  
- Careful review of gluten-free adherence by a skilled dietitian 
- Obtain IgA-tissue transglutaminase antibody (TTG) 
- If TTG abnormal, reinforce dietary adherence and reassess 
- If TTG normal (or remains abnormal on reassessment despite a strict gluten-free diet), 
obtain small intestinal biopsy to rule our refractory celiac disease   
- If biopsy normal, investigate for alternative diagnoses (Table 2) 
Table 3. An Approach to Assessment of Non-Responsive Celiac Disease 
9. Refractory celiac disease 
Refractory celiac disease (RCD) or refractory sprue refers to initial or subsequent failure of a 
strict gluten-free diet to restore normal intestinal architecture and function in patients who 
have celiac-like enteropathy and have no evidence of other pathology including intestinal 
lymphoma. 
Weight loss and diarrhoea are the most consistent symptoms of RCD. The diagnosis 
requires a small intestinal biopsy. Based on the histological appearance of the small 
intestinal mucosa, RCD is divided into two types. In RCD type-1 there is apparently a 
normal intraepithelial lymphocyte phenotype whereas in RCD type-2 there is monoclonal or 
polyclonal expansion of an aberrant intraepithelial lymphocyte population as shown by 
histochemical staining (Freeman, 2008). This latter type carries a high risk of overt 
enteropathy associated T cell lymphoma (EATL) and is associated with a greater mortality 
at two years (41%) compared to RCD type-I (14%).  
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Corticosteroid therapy may improve clinical symptoms in some patients with RCD but the 
response is not consistent. Patients with RCD type-1 often require immunosuppressive 
therapy. The treatment of RCD type-2 is unsatisfactory and the disease carries a high 
mortality with most patients dying within two years of diagnosis (Rubio-Tapia et al. 2009, 
Malamut et al. 2009). A variety of therapies have been tried including azathioprine, anti-
tumor necrosis factor-alpha, cladribine, anti-CD-52, IL-15 antagonists and stem cell 
transplantation to replace the abnormal lymphocyte population. Because of the complex 
nature of therapy, RCD type-2 is best managed by centers with expertise in this condition. 
10. Monitoring of complications 
The two major complications of celiac disease that require careful monitoring include 
development of other autoimmune disorders and malignancy.  
There is controversy whether a gluten-free diet prevents the development of other 
autoimmnune diseases (Ventura et al. 1999, Viljamaa et al. 2005, Sategna Guidetti et al. 
2001). Molecular mimicry, one of the proposed mechanisms for autoimmunity, does 
implicate ongoing gluten exposure. Continued gluten ingestion may also contribute to 
systemic symptoms and development of other disorders like osteoporosis from 
production and circulation of pro-inflammatory cytokines (Fornari et al. 1998, Romaldini 
et al. 2002).  
While a gluten-free diet may not completely eliminate risk of developing other autoimmune 
disorders, continued ingestion of gluten definitely increases the risk. This information may 
also help motivate patients to stay strictly gluten-free. 
Patients with untreated celiac disease have a higher risk of developing malignancy 
compared to the general population. Such malignancies include lymphoma and 
oropharyngeal, esophageal and small intestinal cancer. A careful history, physical 
examination and appropriate investigations should be conducted in patients who are either 
non-adherent to the diet or who remain symptomatic despite following a strict gluten-free 
diet.  
There is good evidence that a gluten-free diet is protective against the development of 
malignancy. Patients on a strict gluten-free diet for >5 years have the same overall risk for 
cancer as the general population (Cooper et al, 1982, Holmes et al. 1989). This information 
should be shared with patients to provide them with reassurance and encouragement for 
strict adherence to the diet. 
11. Ongoing emotional and psychological support 
The diagnosis of celiac disease can be overwhelming and coping with it challenging. 
Patients may feel depressed to learn that they can never eat wheat products again. Feelings 
of anxiety, anger, deprivation and frustration may develop. Eating in social situations can be 
especially problematic (Rashid et al. 2005, Zarkadas et al. 2006). Pressures from the extra 
time and cost involved in buying/preparing foods, along with competing priorities like 
family, job, etc. may further impair coping abilities and act as barriers to compliance. 
Dietary transgressions often occur in adolescents and young adults because of the need to 
conform to peers in social situations. 
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Long-term follow-up of patients with celiac disease will help monitor both their physical 
and psychological well being and maintain trust in the physician and dietitian. Normal 
physical examination and test results will provide patients on a strict gluten-free diet 
reassurance and encouragement. Abnormal test results can be a powerful motivator 
especially for those who do not get symptoms when they eat gluten-containing foods. 
Ongoing psychological support counseling improves compliance with gluten-free diet 
especially in patients with anxiety and depression (Addolorato et al. 2004). 
A referral to a professional psychologist may be required in select cases to help improve the 
patient’s coping skills.  
12. Role of patient advocacy groups 
Patient and family support and advocacy groups can help support patients with celiac 
disease who are starting a gluten-free diet. Models such as the Expert Patients Program in 
the United Kingdom in which individuals learn from each other how to cope with the 
challenges of a chronic condition can be used (Donaldson et al. 2003). Volunteer celiac 
support organizations in several countries provide excellent resources to their members and 
keep them updated on new developments. Physicians and patients have identified such 
organization as important sources of information (Zarkadas et al. 2006). Physicians should 
recommend their patients with celiac disease to become members of such support groups.  
13. Conclusions 
Celiac disease is not a trivial disorder. While most patients do well on a gluten-free diet, 
some do not. Complications including nutritional deficiencies, risk of developing other 
autoimmune disorders, refractory celiac disease and malignancy are important 
considerations. Symptoms alone do not provide a reliable guide to the presence of 
complications. In future, better stratification of risk factors for developing complications 
may allow for individualized follow-up plans for specific patients. All patients with celiac 
disease should have regular, systematic follow-up by a health care team that includes a 
physician and a dietitian.  
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